The Outsourcing Facilities Association and FarmaKeio Custom Compounding filed a similar lawsuit against the agency last year over its removal of tirzepatide, the active ingredient in Eli Lilly's rival weight-loss and diabetes drugs Zepbound and Mounjaro, from the shortage list. That case remains pending, with the association seeking a preliminary ruling blocking the FDA's decision. Read more: https://pharma.economictimes.indiatimes.com/news/pharma-industry/drug-compounders-sue-us-fda-over-removal-of-wegovy-ozempic-from-shortage-list/118555066